Status:
COMPLETED
Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)
Lead Sponsor:
Karolinska Institutet
Collaborating Sponsors:
Region Stockholm
Aerocrine AB
Conditions:
Allergic Asthma
Eligibility:
All Genders
18-64 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allerg...
Eligibility Criteria
Inclusion
- Age 18-64
- Clinical diagnosis of Asthma
- Glucocorticoid treatment \> 6 months.
- Verified Allergy
- Read and speak Swedish
Exclusion
- Smoking
- Current regular treatment with long-acting beta2-agonist
- Treatment with Singulair only or in combination with glucocorticoids
- Taking part in other research study
- Pregnancy or breast-feeding
- Unstable Asthma
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
187 Patients enrolled
Trial Details
Trial ID
NCT00421018
Start Date
November 1 2006
End Date
April 1 2010
Last Update
August 15 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Runby Primary Health Care Center
Upplands Vasby, Sweden